Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.
Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 13, 8, 3, 42, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
A6 Pharmaceuticals LLC
Abbreos Inc
AcelRx Pharmaceuticals Inc
Akttyva Therapeutics Inc
Alveolus Bio Inc
AMNICELL Corp Ltd
Ampio Pharmaceuticals Inc
APEIRON Biologics AG
ARBORMED Pharmaceuticals Inc
Arch Biopartners Inc
Athersys Inc
Avalon GloboCare Corp
Aviceda Therapeutics
AVM Biotechnology LLC
Bayer AG
Biocon Ltd
BioMarck Pharmaceuticals Ltd
BioStem Technologies Inc
Bioxytran Inc
Bonus BioGroup Ltd
Cartesian Therapeutics Inc
Cellular Biomedicine Group Ltd
Cellvation Inc
Celularity Inc
Curacle Co Ltd
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dianomi Therapeutics Inc
Emergent BioSolutions Inc
Endece LLC
Enlivex Therapeutics Ltd
Eunoia Biotech LLC
Exvastat Ltd
Faron Pharmaceuticals Oy
GentiBio Inc
Green Cross LabCell Corp
Grifols SA
Haisco Pharmaceutical Group Co Ltd
Histocell SL
ImmunityBio Inc
Implicit Bioscience Ltd
Imstem Biotechnology Inc
In2cure AB
IsletOne AB
Kalvista Pharmaceuticals Inc
Kubota Vision Inc
Kyorin Pharmaceutical Co Ltd
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
MannKind Corp
MDI Therapeutics Inc
MediPost Co Ltd
Medsenic SAS
Meridigen Biotech Co Ltd
Nano Biotherapeutics Inc
Neutrolis Inc
Northern Therapeutics Inc
NS Pharma Inc
Nuvara Therapeutics LLC
OGB1 Inc
Omnispirant Ltd
Orion Biotechnology Canada Ltd
Pantherna Therapeutics GmbH
PharmAbcine Inc
Restore Therapeutics LLC
RION Health Inc
Shanghai Henlius Biotech Inc
SolAeroMed Inc
Sorrento Therapeutics Inc
Systimmune Inc
Thetis Pharmaceuticals LLC
Vasomune Inc
Veru Inc
Windtree Therapeutics Inc
Xfibra Inc
Xintela AB
ZyVersa Therapeutics Inc
- Introduction
- Global Markets Direct Report Coverage
- Acute Respiratory Distress Syndrome - Overview
- Acute Respiratory Distress Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Acute Respiratory Distress Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
- A6 Pharmaceuticals LLC
- Abbreos Inc
- AcelRx Pharmaceuticals Inc
- Akttyva Therapeutics Inc
- Alveolus Bio Inc
- AMNICELL Corp Ltd
- Ampio Pharmaceuticals Inc
- APEIRON Biologics AG
- ARBORMED Pharmaceuticals Inc
- Arch Biopartners Inc
- Athersys Inc
- Avalon GloboCare Corp
- Aviceda Therapeutics
- AVM Biotechnology LLC
- Bayer AG
- Biocon Ltd
- BioMarck Pharmaceuticals Ltd
- BioStem Technologies Inc
- Bioxytran Inc
- Bonus BioGroup Ltd
- Cartesian Therapeutics Inc
- Cellular Biomedicine Group Ltd
- Cellvation Inc
- Celularity Inc
- Curacle Co Ltd
- Cytonus Therapeutics Inc
- Daewoong Pharmaceutical Co Ltd
- Dianomi Therapeutics Inc
- Emergent BioSolutions Inc
- Endece LLC
- Enlivex Therapeutics Ltd
- Eunoia Biotech LLC
- Exvastat Ltd
- Faron Pharmaceuticals Oy
- GentiBio Inc
- Green Cross LabCell Corp
- Grifols SA
- Haisco Pharmaceutical Group Co Ltd
- Histocell SL
- ImmunityBio Inc
- Implicit Bioscience Ltd
- Imstem Biotechnology Inc
- In2cure AB
- IsletOne AB
- Kalvista Pharmaceuticals Inc
- Kubota Vision Inc
- Kyorin Pharmaceutical Co Ltd
- Liminal BioSciences Inc
- LTT Bio-Pharma Co Ltd
- MannKind Corp
- MDI Therapeutics Inc
- MediPost Co Ltd
- Medsenic SAS
- Meridigen Biotech Co Ltd
- Nano Biotherapeutics Inc
- Neutrolis Inc
- Northern Therapeutics Inc
- NS Pharma Inc
- Nuvara Therapeutics LLC
- OGB1 Inc
- Omnispirant Ltd
- Orion Biotechnology Canada Ltd
- Pantherna Therapeutics GmbH
- PharmAbcine Inc
- Restore Therapeutics LLC
- RION Health Inc
- Shanghai Henlius Biotech Inc
- SolAeroMed Inc
- Sorrento Therapeutics Inc
- Systimmune Inc
- Thetis Pharmaceuticals LLC
- Vasomune Inc
- Veru Inc
- Windtree Therapeutics Inc
- Xfibra Inc
- Xintela AB
- ZyVersa Therapeutics Inc
- Acute Respiratory Distress Syndrome - Drug Profiles
- (cannabidiol + hydroxychloroquine) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- A6-5188 - Drug Profile
- Product Description
- Mechanism Of Action
- AB-5000 - Drug Profile
- Product Description
- Mechanism Of Action
- ABB-201 - Drug Profile
- Product Description
- Mechanism Of Action
- abivertinib maleate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AKT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- alpha-1 proteinase inhibitor (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Ampion - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APN-01 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ApoCell - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ARBM-201 - Drug Profile
- Product Description
- Mechanism Of Action
- AV-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AVD-1010 - Drug Profile
- Product Description
- Mechanism Of Action
- BAY-1097761 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BAY-1211163 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BDTp-231 - Drug Profile
- Product Description
- Mechanism Of Action
- BIO-11006 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologic for Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- Biologic for Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Respiratory - Drug Profile
- Product Description
- Mechanism Of Action
- Biologics for Acute Respiratory Distress Syndrome and Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- BSEM-001 - Drug Profile
- Product Description
- Mechanism Of Action
- BSEM-002 - Drug Profile
- Product Description
- Mechanism Of Action
- BSEM-003 - Drug Profile
- Product Description
- Mechanism Of Action
- BXT-25 - Drug Profile
- Product Description
- Mechanism Of Action
- CBMSC-1 - Drug Profile
- Product Description
- Mechanism Of Action
- CEVA-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CT-303 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CU-06 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CYNK-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Descartes-30 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dexamethasone sodium phosphate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs for Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- DTX-020 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DWP-710 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- HCR-040 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HLX-70 - Drug Profile
- Product Description
- Mechanism Of Action
- HSK-31858 - Drug Profile
- Product Description
- Mechanism Of Action
- ibudilast - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IC-14 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IC-200 - Drug Profile
- Product Description
- Mechanism Of Action
- ilginatinib - Drug Profile
- Product Description
- Mechanism Of Action
- imatinib mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IMS-001 - Drug Profile
- Product Description
- Mechanism Of Action
- interferon beta-1a - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- invimestrocel - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IO-2 - Drug Profile
- Product Description
- Mechanism Of Action
- itolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KV-998052 - Drug Profile
- Product Description
- Mechanism Of Action
- LT-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LTX-608 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MCS-222 - Drug Profile
- Product Description
- Mechanism Of Action
- MDI-2517 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MesenCure - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Metablok - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NAV-5093 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NDC-1308 - Drug Profile
- Product Description
- Mechanism Of Action
- NTR-452 - Drug Profile
- Product Description
- Mechanism Of Action
- OB-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OS-002 - Drug Profile
- Product Description
- Mechanism Of Action
- PAN-004 - Drug Profile
- Product Description
- Mechanism Of Action
- PAN-006 - Drug Profile
- Product Description
- Mechanism Of Action
- PAN-007 - Drug Profile
- Product Description
- Mechanism Of Action
- Peptide for Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- piceatannol albumin bound - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- plasminogen (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PMC-402 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Polymer for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PXVX-0047 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REGEND-007 - Drug Profile
- Product Description
- Mechanism Of Action
- REGEND-008 - Drug Profile
- Product Description
- Mechanism Of Action
- S-1229 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- sabizabulin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SIF-019 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- simvastatin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Activate Sphingosine 1-Phosphate Receptor for Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit VAP-1 for Ophthalmology and Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- SMUPIV-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Stem Cell Therapy for Infectious Diseases and Respiratory Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- TCP-25 - Drug Profile
- Product Description
- Mechanism Of Action
- TP-317 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- UMC-11906 - Drug Profile
- Product Description
- Mechanism Of Action
- UMC-11912 - Drug Profile
- Product Description
- Mechanism Of Action
- Viral Acute Respiratory Distress Syndrome (V-ARDS) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VS-025 - Drug Profile
- Product Description
- Mechanism Of Action
- XFB-19 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XSTEM - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Acute Respiratory Distress Syndrome - Dormant Projects
- Acute Respiratory Distress Syndrome - Discontinued Products
- Acute Respiratory Distress Syndrome - Product Development Milestones
- Featured News & Press Releases
- Feb 17, 2022: Healios plans preapplication consultation with PMDA on MultiStem as early as March
- Feb 03, 2022: Faron Pharmaceuticals : Scientific reports publishes INFORAAA results showing traumakine-induced up-regulation of CD73 prevents death after emergency open aortic surgery
- Jan 26, 2022: Athersys to host a virtual presentation on its MultiStem programs
- Nov 30, 2021: Report of placebo-controlled clinical trial evaluating Multistem cell therapy for acute respiratory distress syndrome published in intensive care medicine
- Nov 12, 2021: Athersys reports updates on timing for Japan ARDS and stroke programs from Healios K.K.
- Sep 28, 2021: Athersys to present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference
- Aug 09, 2021: Healios reports positive data of cell therapy in ARDS patients
- Jul 21, 2021: Enlivex to present at the Improvate Life-Saving Technologies International Conference 2021
- Jul 14, 2021: Enlivex to present at the ARDS Drug Development Summit 2021
- Jul 07, 2021: Results of Biomarck clinical and preclinical studies of BIO-11006 in ARDS to be presented at the 2021 ARDS Drug Development Summit
- Jun 30, 2021: New publication provides further clarity of multistem's mechanism of action on modulating the inflammatory response in critical care indications
- Jun 28, 2021: MediciNova to conduct mouse study under partnership with BARDA to develop MN-166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury
- May 12, 2021: Results of Biomarck phase II study of BIO-11006 in patients with ARDS to be presented at the 2021 ATS Annual Meeting
- Apr 06, 2021: Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
- Mar 31, 2021: Athersys reports that healios has completed enrollment in the ONE-BRIDGE study of MultiStem for Acute Respiratory Distress Syndrome in Japan
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Acute Respiratory Distress Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Companies, 2022 (Contd..2)
- Number of Products under Development by Companies, 2022 (Contd..3)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Companies, 2022 (Contd..3)
- Products under Development by Companies, 2022 (Contd..4)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Abbreos Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by AcelRx Pharmaceuticals Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Akttyva Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Alveolus Bio Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by AMNICELL Corp Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Ampio Pharmaceuticals Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by APEIRON Biologics AG, 2022
- Acute Respiratory Distress Syndrome - Pipeline by ARBORMED Pharmaceuticals Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Arch Biopartners Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Avalon GloboCare Corp, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Aviceda Therapeutics, 2022
- Acute Respiratory Distress Syndrome - Pipeline by AVM Biotechnology LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Biocon Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by BioMarck Pharmaceuticals Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by BioStem Technologies Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Bioxytran Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Bonus BioGroup Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Cartesian Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Cellular Biomedicine Group Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Cellvation Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Celularity Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Curacle Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Cytonus Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Dianomi Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Emergent BioSolutions Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Endece LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Enlivex Therapeutics Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Eunoia Biotech LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Exvastat Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, 2022
- Acute Respiratory Distress Syndrome - Pipeline by GentiBio Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Green Cross LabCell Corp, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Grifols SA, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Histocell SL, 2022
- Acute Respiratory Distress Syndrome - Pipeline by ImmunityBio Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Imstem Biotechnology Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by In2cure AB, 2022
- Acute Respiratory Distress Syndrome - Pipeline by IsletOne AB, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Kalvista Pharmaceuticals Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Kubota Vision Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Liminal BioSciences Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by LTT Bio-Pharma Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by MannKind Corp, 2022
- Acute Respiratory Distress Syndrome - Pipeline by MDI Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by MediPost Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Medsenic SAS, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Meridigen Biotech Co Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Nano Biotherapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Neutrolis Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Northern Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by NS Pharma Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Nuvara Therapeutics LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by OGB1 Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Omnispirant Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Orion Biotechnology Canada Ltd, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Pantherna Therapeutics GmbH, 2022
- Acute Respiratory Distress Syndrome - Pipeline by PharmAbcine Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Restore Therapeutics LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by RION Health Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Shanghai Henlius Biotech Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Sorrento Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Systimmune Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Thetis Pharmaceuticals LLC, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Vasomune Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Veru Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Xfibra Inc, 2022
- Acute Respiratory Distress Syndrome - Pipeline by Xintela AB, 2022
- Acute Respiratory Distress Syndrome - Pipeline by ZyVersa Therapeutics Inc, 2022
- Acute Respiratory Distress Syndrome - Dormant Projects, 2022
- Acute Respiratory Distress Syndrome - Dormant Projects, 2022 (Contd..1)
- Acute Respiratory Distress Syndrome - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Acute Respiratory Distress Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook